Hot Search:

C57BL/6JGpt-H11em1Cin(K18-hACE2)/Gpt

H11-K18-hACE2|Strain NO.T037657

Knockin (KI)

  • Product Type:
  • Quantity: - +
  • Sex:
  • Age:
  • Genotype:
BASIC INFORMATION
Strain Name: C57BL/6JGpt-H11em1Cin(K18-hACE2)/Gpt
Strain Number: T037657
Official Symbol: ACE2,H11
Strain Strategy: T037657.H11-K18-hACE2 strain info.pdf
Official Full Name: angiotensin I converting enzyme 2
Also Known As: ACEH,hACE2
NCBI Number: 59272
Chromosome: 11
Research Areas: Humanized model,Gene humanization model
Strain Background: [N000013] C57BL/6JGpt
Modification Type: Knockin (KI)
Inventory Status: Live,Cryopreserved
Sale Status: IF (Available for Distribution)
Health Status: Specific pathogen free (SPF)
Health Report: Please log in to view
Publications: 1. Development of highly effective LCB1-based lipopeptides targeting the spike receptor-binding motif of SARS-CoV-22. Recombinant chimpanzee adenovirus vector vaccine expressing the spike protein provides effective and lasting protection against SARS-CoV-2 infection in mice3. SARS-CoV-2 crosses the blood–brain barrier accompanied with basement membrane disruption without tight junctions alteration4. Identification of potent human neutralizing antibodies against SARS-CoV-2 implications for development of therapeutics and prophylactics5. Sequential infection with H1N1 and SARS-CoV-2 aggravated COVID-19 pathogenesis in a mammalian model, and co-vaccination as an effective method of prevention of COVID-19 and influenza6. Coinfection with influenza A virus enhances SARS-CoV-2 infectivity7. SARS-CoV-2 binds platelet ACE2 to enhance thrombosis in COVID-198. A combination vaccine against SARS-CoV-2 and H1N1 influenza based on receptor binding domain trimerized by six-helix bundle fusion core9. In vitro and in vivo evaluation of the main protease inhibitor FB2001 against SARS-CoV-210. NSUN2-mediated M(5)c methylation of IRF3 mRNA negatively regulates type I interferon responses during various viral infections11. Mouse models susceptible to HCoV-229E and HCoV-NL63 and cross protection from challenge with SARS-CoV-212. Inhalation delivery of dexamethasone with iSEND nanoparticles attenuates the COVID-19 cytokine storm in mice and nonhuman primates13. Soluble CD4 effectively prevents excessive TLR activation of resident macrophages in the onset of sepsis14. Broadly neutralizing antibodies derived from the earliest COVID-19 convalescents protect mice from SARS-CoV-2 variants challenge15. A viral RNA-dependent RNA polymerase inhibitor VV116 broadly inhibits human coronaviruses and has synergistic potency with 3CLpro inhibitor nirmatrelvir16. Independent Protection and Influence of the Spike-Specific Antibody Response of SARS-CoV-2 Nucleocapsid Protein (N) in Whole-Virion Vaccines17. Structure-based development and preclinical evaluation of the SARS-CoV-2 3C-like protease inhibitor simnotrelvir18. Intranasal mask for protecting the respiratory tract against viral aerosols19. Protection of the receptor binding domain (RBD) dimer against SARS-CoV-2 and its variants20. Preclinical evaluation of the SARS-CoV-2 M(pro) inhibitor RAY1216 shows improved pharmacokinetics compared with nirmatrelvir21. An intranasal combination vaccine induces systemic and mucosal immunity against COVID-19 and influenza22. An optimized high-throughput SARS-CoV-2 dual reporter trans-complementation system for antiviral screening in vitro and in vivo23. Oncolytic adenovirus encoding apolipoprotein A1 suppresses metastasis of triple-negative breast cancer in mice24. Helminth alleviates COVID-19-related cytokine storm in an IL-9-dependent way25. The lethal K18-hACE2 knock-in mouse model mimicking the severe pneumonia of COVID-19 is practicable for antiviral development26. Deciphering a reliable synergistic bispecific strategy of rescuing antibodies for SARS-CoV-2 escape variants, including BA.2.86, EG.5.1, and JN.127. A broad neutralizing nanobody against SARS-CoV-2 engineered from an approved drug28. Sanhan Huashi Formula and Its Bioactive Compounds Exert Antiviral and Anti-Inflammatory Effects on COVID-1929. Immunogenicity and protective efficacy of the HC009 mRNA vaccine against SARS-CoV-230. A decavalent composite mRNA vaccine against both influenza and COVID-1931. Cdc42 improve SARS-CoV-2 spike protein-induced cellular senescence through activating of Wnt/β-Catenin signaling pathway32. A substitution at the cytoplasmic tail of the spike protein enhances SARS-CoV-2 infectivity and immunogenicity33. Nonenzymatic lysine d-lactylation induced by glyoxalase II substrate SLG dampens inflammatory immune responses